CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Inhibikase Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Inhibikase Therapeutics Inc
3350 Riverwood Parkway Se, Suite 1900
Phone: (678) 392-3419p:678 392-3419 ATLANTA, GA  30339  United States Ticker: IKTIKT
Business Summary
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes-Yes-

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Amit D.Munshi 56 2/14/2025 10/21/2024
President, Head - Research and Development Christopher H.Cabell 56 2/21/2025 2/21/2025
Chief Executive Officer, Principal Executive Officer, Director Mark T.Iwicki 58 2/14/2025 2/14/2025
6 additional Officers and Directors records available in full report.

Business Names
Business Name
CorHepta Pharmaceuticals, Inc.
IKT
IKT Securities Corporation
IQT

General Information
Number of Employees: 15 (As of 3/27/2025)
Outstanding Shares: 74,341,540 (As of 3/20/2025)
Shareholders: 29
Stock Exchange: NASD
Federal Tax Id: 263407249
Fax Number: (302) 655-5049
Email Address: info@inhibikase.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025